Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.”
Email: jackfriday2011(at)hotmail.co.uk
Monday, April 23, 2007
Are AstraZeneca paying over the top for MedImmune?
AstraZeneca's stock tumbled Monday after announcing it will pay more than $15 billion to acquire MedImmune, a deal that analysts are calling too expensive.
No comments:
Post a Comment